Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep917 | Pituitary - Clinical | ECE2016

The role of p16 and MDM2 gene polymorphisms in tumorigenesis and characteristics of prolactinoma

Turgut Seda , Ilhan Muzaffer , Turan Saime , Karaman Ozcan , Yaylim Ilhan , Kucukhuseyin Ozlem , Tasan Ertugrul

Introduction: Prolactinomas are thought to arise from the proliferation of a mutated pituitary stem cell which is subjected to the growth stimuli of several permissive factors, although the pathogenetic mechanisms underlying the tumorigenesis still remain unclear. The present study aimed to investigate the role of p16 (540C→G and 580C→T) and MDM2 (SNP309T→G) gene polymorphisms in tumorigenesis and characteristics of prolactinoma.Methods...

ea0037ep555 | Obesity and cardiovascular endocrinology | ECE2015

Weight loss with bariatric surgery improves ischaemia modified albumin levels and oxidative status in morbidly obese patients

Yay Adnan , Ilhan Muzaffer , Turan Saime , Zeybek Umit , Karaman Ozcan , Yaylim Ilhan , Tasan Ertugrul

Introduction: Oxidative stress is one of the possible mechanisms involved in the pathogenesis of the obesity-related metabolic complication. In this study, we aimed to investigate effect of weight loss with bariatric surgery on IMA, high sensitive C-reactive protein (hs-CRP), serum total antioxidant status (TAS), total oxidant status (TOS) levels.Materials and methods: In this prospective study, plasma IMA, hs-CRP, TAS and TOS levels were measured before...

ea0035oc1.1 | Thyroid clinical | ECE2014

Esophagus motility in overt hypothyroidism

Ilhan Mahmut Muzaffer , Arabaci Elif , Turgut Seda , Karaman Ozcan , Danalioglu Ahmet , Tasan Ertugrul

Introduction: Gastrointestinal tract is one of the most affected systems in hypothyroidism. The most plausible mechanism in the pathogenesis is the development of interstitial edema subsequent to accumulation of glycosaminoglycans. Despite decreased esophageal emptying, prolonged esophageal and gastric transit time has been indicated in previous reports, the mechanism of thyroid hormones activity on the gastrointestinal system is not yet fully understood. To our knowledge, thi...

ea0026p5 | Adrenal cortex | ECE2011

The utility of FDG-PET CT in differentiating malignant from benign adrenal lesions

Oguz Basak , Zuhur Sayid Shafi , Karaman Ozcan , Velet Selvinaz , Altuntas Yuksel

Background: With the increasing use of USG, MRI and CT, adrenal lesions are frequently found in the daily practice. These lesions may be primary or secondary in origin. However, it is important to resolve whether these lesions are benign or malignant.Purpose: The aim of this case detection study was to compare FDG-PET CT with MRI in differentiating benign from malignant adrenal mass lesions.Patients: All patients were admitted to o...

ea0026p585 | Clinical case reports | ECE2011

Coexistence of double small insulinomas with a small glucagonoma in a patient with multiple endocrine neoplasia-type 1 (MEN-1)

Zuhur Sayid Shafi , Karaman Ozcan , Yildirim Sumeyra , Erdamar Sibel , Senturk Hakan , Altuntas Yuksel

Background: MEN-1 is a rare disease characterized by parathyroid adenoma or hyperplasia, pituitary adenoma and pancreatic neuroendocrine tumors (PNET). Gastrinomas are the most common functional PNET in MEN-1 disease. Insulinomas and glucagonomas constitute approximately 20 and 3% of PNET’s in MEN-1 disease. Most of insulinomas are benign in nature but about 70% of cases of glucagonomas present with metastasis at diagnosis. Coexistence of various PNET’s are very rare...

ea0026p712 | Diabetes (epidemiology, pathophysiology) | ECE2011

The frequency of Cushing's disease among obese, type 2 diabetes mellitus patients: a single center experience in Turkey

Karaman Ozcan , Zuhur Sayid Shafi , Cil Esra , Ozderya Aysenur , Ozturk Feyza Yener , Altuntas Yuksel

Background: Obesity and diabetes mellitus (DM) are the features of Cushing’s disease (CD). Studies indicated different frequencies of CD among obese, type 2 DM patients. The frequency of CD among obese, type 2 DM have’nt been studied in Turkey. Therefore, we aimed to assess the frequency of CD among obese (BMI>30 kg/m2) type 2 DM patients that had not classical morphological findings of CD.Patients and methods: Two hundred consec...

ea0022p569 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Unsatisfied treatment outcomes of acromegaly patients: a single center experience in Turkey

Ozturk Feyza Yener , Cil Esra , Ozderya Aysenur , Karaman Ozcan , Zuhur Sayid Shafi , Altuntas Yuksel

Background: Acromegaly is a multi-systemic dysfiguring disease caused by pituitary GH secreting tumour. Pituitary surgery, medical treatment with somatostatin analogues and radiotherapy have been cornerstone in the management of acromegaly. However, all these treatment modalities do not provide sufficient disease control especially in patients with macroadenomas.Objective: To evaluate the follow-up outcomes and remission rates of acromegaly patients....

ea0026p206 | Pituitary | ECE2011

O-6 methylguanine-DNA methyl transferase (MGMT) immunoexpression in GH secreting pituitary adenomas and it’s correlation with Ki-67 labeling index (Ki-67 LI)

Zuhur Sayid Shafi , Tanik Canan , Karaman Ozcan , Cil Esra , Velet Selvinaz , Ozturk Feyza Yener , Musluman Ahmet Murat , Altuntas Yuksel

Background: Currently, multiple treatment options are available for the treatment of acromegaly. However, cure is obtained only in 50% of patients with macroadenomas after surgery. Persistent tumor enlargement occur in 2.2% of the patients treated with somatostatin analogs and in 1.6–2.9% of the patients treated with pegvisomant. The nuclear antigen Ki-67 is related to growth potential and is also a major prognostic indicator for pituitary adenomas. Studies demonstrated t...

ea0026p583 | Clinical case reports | ECE2011

MGMT immunoexpression in adamantinomatous craniopharyngiomas

Zuhur Sayid Shafi , Musluman Ahmet Murat , Tanik Canan , Karaman Ozcan , Ozturk Feyza Yener , Ozkayalar Hanife , Altuntas Yuksel

Background: Currently, no effective medical treatment exists for recurrent and aggressive craniopharyngiomas that are resistant to conventional therapies, including repeat surgeries and adjuvant radiotherapy (RT). Temozolomide is an alkylating chemotherapeutic agent and is used routinely in the management of high grade gliomas. The response to temozolomide is suggested to be dependent on the tumoral expression of O-6 methylguanine DNA methyltransferase (MGMT). Evidence ...